STAAR Surgical Q1 Surge Post-Alcon Block

STAAR Surgical posted Q1 2026 GAAP EPS $0.10, net sales $93.5 million, up 119.6% YoY, beating estimates.
Operating income swung to $8.0 million from a $57.4 million loss, and adjusted EBITDA turned to $24.4 million profit.
After shareholders rejected Alcon’s $30.75 per‑share buyout, STAAR added three directors and appointed Warren Foust and Deborah Andrews as interim Co‑CEOs.
China sales drove recovery with $47.4 million net sales; U.S. sales rose 22% YoY to $6 million despite a 7% drop in laser‑vision volumes.